
Opinion|Videos|January 9, 2025
KEYONTE-522: Exploratory Biomarker Analysis in Periop Pembro vs. Placebo + Chemo
Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.





































